| Accession | Title | Sample type | Organism(s) | Ch | Platform | Series | Supplementary | Contact | Release date |
|---|---|---|---|---|---|---|---|---|---|
 Filter
|
GSE165052
|
SRA Run Selector
|
|||||||
| GSM4988749 |
P2A1: Sensitive PH039 third passage source tumor
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM4988750 |
P2A2: Sensitive PH039 third passage source tumor
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM4988751 |
P2A3: Sensitive PH039 third passage source tumor
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM4988752 |
F1A3: Sensitive PH039 first passage niraparib treated tumor
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM4988753 |
F1A4: Sensitive PH039 first passage niraparib treated tumor
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM4988754 |
F1A5: Mixed phenotype PH039 first passage niraparib treated tumor
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM4988755 |
F251: Mixed phenotype PH039 first passage niraparib treated tumor
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM4988756 |
F351: Resistant PH039 second passage niraparib treated tumor
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM4988757 |
F352: Resistant PH039 second passage niraparib treated tumor
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM4988758 |
F451: Resistant PH039 third passage niraparib treated tumor
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM4988759 |
F452: Resistant PH039 third passage niraparib treated tumor
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM4988760 |
F453: Resistant PH039 third passage niraparib treated tumor
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM5025311 |
S0.2: Sensitive PH039 source tumor (rrbs)
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM5025312 |
S2.1: Sensitive PH039 second passage source tumor (rrbs)
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM5025313 |
S5.3: Sensitive PH039 fifth passage source tumor (rrbs)
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM5025314 |
S5.4: Sensitive PH039 fifth passage source tumor (rrbs)
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM5025315 |
C1.1: PH039 first passage niraparib treated tumor (rrbs)
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM5025316 |
C1.2: PH039 first passage niraparib treated tumor (rrbs)
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM5025317 |
C2.1: PH039 second passage niraparib treated tumor (rrbs)
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 | ||
| GSM5025318 |
C2.2: PH039 second passage niraparib treated tumor (rrbs)
|
SRA | 1 |
|
|
Hu Li | Jun 16, 2021 |
